Ranked by engagement
Top topics — all time page 31
Ranked by replies, likes and views over all time, with a bonus for topics that reached a marked solution. Engagement is a proxy for usefulness and a poor one; the documentation commons is the better index of what is settled.
1,535 topics · page 31 of 40
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Personal or family history of medullary thyroid carcinoma
Personal or family history of medullary thyroid carcinoma Writing it up because I had to work it out twice and would rather nobody else did. Asking about a population rather than about a person. The published…
|
+31 | 37 | 709 | 26d |
|
What published stability data actually covers, and what it does not — what changed since
What published stability data actually covers, and what it does not — what changed since — that is the question, and I have not found it answered plainly anywhere I have looked. Practical question with the…
|
3 | 43k | 6mo | |
|
[2026 update] Conference abstracts as evidence: the weakest common citation
Conference abstracts as evidence: the weakest common citation — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA , 2021) with SURMOUNT-4 ( JAMA , 2024) and finding…
|
2 | 48k | 7mo | |
|
[2026 update] Hello from a laboratory that does not do peptides
Hello from a laboratory that does not do peptides Writing it up because I had to work it out twice and would rather nobody else did. Lower-stakes topic, but the sourcing rule still applies if anyone makes a…
|
2 | 49k | 4mo | |
|
A newcomer's list of things that confused me, and the fixes
A newcomer's list of things that confused me, and the fixes — setting out what I have, and where I think it stops being reliable. Question in the title. Context below, and I have tried to include the things…
|
+9 | 13 | 34k | 12mo |
|
Coming back to: Reading a meta-analysis you disagree with, fairly
Reading a meta-analysis you disagree with, fairly Writing it up because I had to work it out twice and would rather nobody else did. I have seen STEP 1 ( N Engl J Med , 2021) cited in support of a claim I do…
|
+30 | 34 | 9.3k | 17mo |
|
AOD-9604 and the fragment hypothesis, revisited — does this still hold?
The question in the title: AOD-9604 and the fragment hypothesis, revisited — does this still hold? I will give what I have already checked below so nobody repeats it. Comparing FLOW ( N Engl J Med , 2024)…
|
+7 | 11 | 31k | 19h |
|
Insurance and replacement policies, compared — the long version
Insurance and replacement policies, compared — the long version — setting out what I have, and where I think it stops being reliable. I would like to talk about documentation quality as a signal, separately…
|
+29 | 33 | 4.9k | 9mo |
|
Coming back to: Injection-site reactions: describing them precisely enough to be useful
On the subject in the title: Injection-site reactions: describing them precisely enough to be useful Working notes rather than a conclusion. Reporting something rather than asking about it, in case the…
|
+21 | 25 | 22k | 8mo |
|
Peer-to-peer review: what actually happens on the call — one year on
Peer-to-peer review: what actually happens on the call — one year on — setting out what I have, and where I think it stops being reliable. Documenting an access outcome, dated, because everything in this…
|
+2 | 6 | 41k | 5mo |
|
About the Contraindications category
Absolute and relative contraindications, and the conditions that change the calculus. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its…
|
+6 | 10 | 35k | 14mo |
|
Random versus fixed effects: choosing rather than defaulting
Random versus fixed effects: choosing rather than defaulting — setting out what I have, and where I think it stops being reliable. Session topic: FLOW ( N Engl J Med , 2024). Please read it before posting;…
|
+16 | 20 | 22k | 13mo |
|
Why side effects reset at each escalation and that is not a failure — the long version
The question in the title: Why side effects reset at each escalation and that is not a failure — the long version I will give what I have already checked below so nobody repeats it. Reporting something rather…
|
2 | 46k | 17mo | |
|
An ABAB design with a data table and honest limitations
An ABAB design with a data table and honest limitations Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SURPASS-4 ( Lancet , 2021). Please read it before…
|
2 | 45k | 5mo | |
|
Bleeding at the injection site: normal, and what to do about it — does this still hold?
Bleeding at the injection site: normal, and what to do about it — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Reporting something rather than…
|
+20 | 24 | 16k | 15mo |
|
Why an oral GLP-1 agonist is a formulation achievement more than a chemistry one — one year on
Asking directly, because I could not find a straight answer: Why an oral GLP-1 agonist is a formulation achievement more than a chemistry one — one year on I have seen SURMOUNT-1 ( N Engl J Med , 2022) cited…
|
+16 | 20 | 18k | 2mo |
|
About the Receptor biology category
GLP-1, GIP, glucagon and amylin receptor signalling, bias, desensitisation and central versus peripheral action. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit…
|
+6 | 10 | 34k | 20d |
|
How this community labels and discusses unrefereed work — the long version
Asking directly, because I could not find a straight answer: How this community labels and discusses unrefereed work — the long version I have seen SURMOUNT-1 ( N Engl J Med , 2022) cited in support of a…
|
+18 | 23 | 21k | 2mo |
|
Reading an MS report that only gives you a single number — the long version
Reading an MS report that only gives you a single number — the long version — setting out what I have, and where I think it stops being reliable. I would like to understand what this number means before I…
|
2 | 47k | 18mo | |
|
Confounding by indication, explained with a concrete example
On the subject in the title: Confounding by indication, explained with a concrete example Working notes rather than a conclusion. Comparing SURMOUNT-1 ( N Engl J Med , 2022) with SURPASS-2 ( N Engl J Med ,…
|
+21 | 25 | 21k | 11mo |
|
I have no scientific background — can I still follow the analytics categories?
The question in the title: I have no scientific background — can I still follow the analytics categories? I will give what I have already checked below so nobody repeats it. I want to check my reasoning…
|
+29 | 40 | 1.4k | 12d |
|
Introducing myself: pharmacist, sceptic, reluctant participant
Introducing myself: pharmacist, sceptic, reluctant participant Writing it up because I had to work it out twice and would rather nobody else did. Lower-stakes topic, but the sourcing rule still applies if…
|
+13 | 17 | 23k | 2mo |
|
Insomnia at a dose step: reported experiences
On the subject in the title: Insomnia at a dose step: reported experiences Working notes rather than a conclusion. General question, not a request for advice about my own care — I know the difference and I…
|
+20 | 24 | 18k | 8mo |
|
How Janoshik, Medutest, PeptideMeter and VendorInvestigate differ — does this still hold?
Asking directly, because I could not find a straight answer: How Janoshik, Medutest, PeptideMeter and VendorInvestigate differ — does this still hold? Structured report rather than an opinion, following the…
|
+24 | 28 | 8k | 1mo |
|
Travelling with an injectable: documentation and practicalities
Posting this under the heading it deserves: Travelling with an injectable: documentation and practicalities Everything below is what sits behind that. Documenting an access outcome, dated, because everything…
|
+37 | 42 | 2.1k | 1d |
|
Excipient function in a licensed injectable
Excipient function in a licensed injectable Writing it up because I had to work it out twice and would rather nobody else did. Posting the method first, because I know what the first three replies will…
|
+3 | 7 | 36k | 14mo |
|
Validating a calculator against hand arithmetic
Validating a calculator against hand arithmetic Writing it up because I had to work it out twice and would rather nobody else did. Working through the identity arithmetic and I would like it checked.…
|
+17 | 21 | 12k | 3mo |
|
Needle changes between doses on a reusable pen — does this still hold?
Needle changes between doses on a reusable pen — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. I have read the maintained page on this and I…
|
+1 | 5 | 38k | 13mo |
|
Follow-up: UK access routes, dated and sourced
On the subject in the title: UK access routes, dated and sourced Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires. As of May 2026, in…
|
+10 | 14 | 27k | 2d |
|
Journal club: the retatrutide phase 2 obesity paper
Journal club: the retatrutide phase 2 obesity paper — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim I do not think it…
|
+7 | 11 | 33k | 7mo |